Ardena

Overview

Ardena is an integrated CDMO and bioanalytical CRO built for the complexity of modern drug development. The company specializes in advanced drug product development, nanomedicine, and bioanalysis, working with molecules that present significant challenges to other CDMOs.

Core Capabilities

Drug Product

• End-to-end development for small molecules with complex profiles
• Bioavailability enhancement
• High potency and controlled substance manufacturing
• Oral solid dosage forms
• Sterile injectable formulations
• Clinical trial supply
• Process chemistry and scale-up
• Polymorph and salt screening
• Analytical method development
• GMP manufacturing

Nanomedicine

• Lipid-based nanoparticles
• Polymeric nanoparticles
• Metal nanoparticles
• ADC and XDC development
• CMC regulatory services

Bioanalysis

• Small and large molecule analysis
• Biomarkers
• Immunogenicity testing
• Flow cytometry
• qPCR
• Clinical trial services
• ADC and XDC analysis

Drug Substance

• PROTACs, glues, and conjugates
• Solid state research
• High potent API (HPAPI) synthesis
• CMC regulatory support

Organization

Ardena operates five purpose-built facilities across Europe and the United States, with approximately 700 employees including 350+ scientists and 150+ PhDs. The company has processed 600+ molecules across its portfolio.